Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy-Reference-Cited by-同舟云学术

Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy

Published:1992-02 Issue:2 Volume:118 Page:157-162
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Yamasaki Seiji,Okino Takashi,Kan Norimichi,Satoh Kohei,Mise Keiichi,Teramura Yasufumi,Harada Takehisa,Kodama Hiroshi,Hori Taisuke,Ohgaki Kazuhisa,Tobe Takayoshi

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/BF01187506.pdf

Reference23 articles.

1. Clark GM, Sledge GW, Osborne CK, McGuire WL (1987) Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5:55?61

2. Cox DR (1972) Regression models and life tables. J R Statist Soc [B] 34:187?220

3. Gehan EA (1965) A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 52:203?224

4. George SL, Hogstraten B (1978) Prognostic factors in the initial response to therapy by patients with advanced breast cancer. J Natl Cancer Inst 60:731?736

5. Guillou PJ (1987) Potential impact of immunobiotechnology on cancer therapy. Br J Surg 74:705?710

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring Factors Related to Metastasis Free Survival in Breast Cancer Patients Using Bayesian Cure Models;Asian Pacific Journal of Cancer Prevention;2014-12-18

2. Locoregional immuno(bio)therapy for liver metastases;Seminars in Oncology;2002-04

3. Prognostic Significance of Liver Metastases as First Site of Generalisation in Patients with Breast Cancer - A Retrospective Analysis;Acta Medica Austriaca;2001-11

4. Docetaxel: a new active agent in the therapy of metastatic breast cancer;Expert Opinion on Investigational Drugs;1997-12

5. OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer;Surgery Today;1994-01